Cargando…

Combination of MiR-103a-3p and Mesothelin Improves the Biomarker Performance of Malignant Mesothelioma Diagnosis

BACKGROUND: For the detection of malignant mesothelioma no single biomarker with reasonable sensitivity and specificity has been described so far. Mesothelin, the most prominent blood-based biomarker, is characterized by high specificity but low sensitivity. It might be reasonable to combine biomark...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weber, Daniel G., Casjens, Swaantje, Johnen, Georg, Bryk, Oleksandr, Raiko, Irina, Pesch, Beate, Kollmeier, Jens, Bauer, Torsten T., Brüning, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255020/ https://www.ncbi.nlm.nih.gov/pubmed/25469901 http://dx.doi.org/10.1371/journal.pone.0114483

Ejemplares similares

Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study
por: Casjens, Swaantje, et al.
Publicado: (2017)

Assessment of miR-103a-3p in leukocytes—No diagnostic benefit in combination with the blood-based biomarkers mesothelin and calretinin for malignant pleural mesothelioma diagnosis
por: Jiménez-Ramírez, Carmina, et al.
Publicado: (2022)

Mesothelin Gene Variants Affect Soluble Mesothelin-Related Protein Levels in the Plasma of Asbestos-Exposed Males and Mesothelioma Patients from Germany
por: Rihs, Hans-Peter, et al.
Publicado: (2022)

Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin – a case-control comparison nested into a prospective cohort of asbestos-exposed workers
por: Johnen, Georg, et al.
Publicado: (2018)

Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma
por: Weber, Daniel G., et al.
Publicado: (2017)

Calretinin as a blood-based biomarker for mesothelioma
por: Johnen, Georg, et al.
Publicado: (2017)

Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer
por: Weber, Daniel Gilbert, et al.
Publicado: (2013)

Circulating long non-coding RNA GAS5 (growth arrest-specific transcript 5) as a complement marker for the detection of malignant mesothelioma using liquid biopsies
por: Weber, Daniel G., et al.
Publicado: (2020)

Re-evaluation of potential predictors of calretinin and mesothelin in a population-based cohort study using assays for the routine application in clinical medicine
por: Casjens, Swaantje, et al.
Publicado: (2021)

Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case–control study
por: Weber, Daniel Gilbert, et al.
Publicado: (2019)

Identification of miRNA-103 in the Cellular Fraction of Human Peripheral Blood as a Potential Biomarker for Malignant Mesothelioma – A Pilot Study
por: Weber, Daniel G., et al.
Publicado: (2012)

Determinants of plasma calretinin in patients with malignant pleural mesothelioma
por: Lehnert, Martin, et al.
Publicado: (2020)

Blood‐based detection of lung cancer using cysteine‐rich angiogenic inducer 61 (CYR61) as a circulating protein biomarker: a pilot study
por: Ac\ˇkar, Lucija, et al.
Publicado: (2021)

Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients
por: Raiko, Irina, et al.
Publicado: (2010)

Assessment of mRNA and microRNA Stabilization in Peripheral Human Blood for Multicenter Studies and Biobanks
por: Weber, Daniel Gilbert, et al.
Publicado: (2010)

Evaluation of a New Survivin ELISA and UBC(®) Rapid for the Detection of Bladder Cancer in Urine
por: Gleichenhagen, Jan, et al.
Publicado: (2018)

Exploring solid-phase proximity ligation assay for survivin detection in urine
por: Gleichenhagen, Jan, et al.
Publicado: (2022)

NOTCH1, HIF1A and Other Cancer-Related Proteins in Lung Tissue from Uranium Miners—Variation by Occupational Exposure and Subtype of Lung Cancer
por: Pesch, Beate, et al.
Publicado: (2012)

Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population
por: Aguilar-Madrid, Guadalupe, et al.
Publicado: (2018)

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Anti-Mesothelin CAR T cell therapy for malignant mesothelioma
por: Castelletti, Laura, et al.
Publicado: (2021)

Soluble Mesothelin-Related Peptides Levels in Patients with Malignant Mesothelioma
por: Franko, Alenka, et al.
Publicado: (2012)

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study
por: Xanthopoulos, Athanasios, et al.
Publicado: (2008)

Level of mesothelin expression can indicate the prognosis of malignant pleural mesothelioma
por: Feng, Feifei, et al.
Publicado: (2020)

Association of MiR-126 with Soluble Mesothelin-Related Peptides, a Marker for Malignant Mesothelioma
por: Santarelli, Lory, et al.
Publicado: (2011)

Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis
por: Tian, Long, et al.
Publicado: (2017)

Cross-Contamination of a UROtsa Stock with T24 Cells – Molecular Comparison of Different Cell Lines and Stocks
por: Johnen, Georg, et al.
Publicado: (2013)

Digital PCR for the Analysis of MYC Copy Number Variation in Lung Cancer
por: Brik, Alexander, et al.
Publicado: (2020)

Cancer Incidence and Mortality in Firefighters
por: Casjens, Swaantje, et al.
Publicado: (2020)

Cancer risks of firefighters: a systematic review and meta-analysis of secular trends and region-specific differences
por: Casjens, Swaantje, et al.
Publicado: (2020)

Author’s reply to: cancer risks of firefighters: a systematic review and meta‑analysis of secular trends and region‑specific differences
por: Casjens, Swaantje, et al.
Publicado: (2021)

Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
por: Cui, Ai, et al.
Publicado: (2014)

Hitting the Bull’s-Eye: Mesothelin’s Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma
por: Yeo, Dannel, et al.
Publicado: (2021)

A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice
por: Linch, Mark, et al.
Publicado: (2014)

Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin
por: Ak, Guntulu, et al.
Publicado: (2017)

Diagnostic Value of the Impairment of Olfaction in Parkinson's Disease
por: Casjens, Swaantje, et al.
Publicado: (2013)

MSLN Gene Silencing Has an Anti-Malignant Effect on Cell Lines Overexpressing Mesothelin Deriving from Malignant Pleural Mesothelioma
por: Melaiu, Ombretta, et al.
Publicado: (2014)

Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis
por: Gao, Ruiyue, et al.
Publicado: (2019)

Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma
por: Qualiotto, Aline Nery, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bq0hr9c98nnnf2j4jipt922bps